Bird Reports 2025 Third Quarter Results; Record $10 Billion Combined Backlog and Pending Backlog GlobeNewswire November 12, 2025 MISSISSAUGA, Ontario, Nov. 12, 2025 (GLOBE NEWSWIRE) — “Sustained demand in Bird's key strategic sectors, along with the Company's proven track record in delivering complex institutional, industrial and infrastructure projects, helped drive Bird's combined Backlog and Pending […]

NEW YORK CITY, NY / ACCESS Newswire / November 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Stride, Inc. ("Stride" or "the Company") (NYSE:LRN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants

(NASDAQ:FFAI), Future FF and FX BEV vehicles equipped with NACS charge ports in North America, Japan and South Korea will gain access to 28,000+ Tesla Superchargers, providing more infrastructure convenience for future drivers. Tesla Supercharger access adds tremendous convenience, reliability and charging speed to the existing charging network that FF and FX users have access

Faraday Future Announces Adoption of North American Charging System (NACS), Providing Future FF and FX Super One Drivers Access to Tesla's Supercharger Network in North America, Japan and South Korea GlobeNewswire November 12, 2025 Future FF and FX BEV vehicles equipped with NACS charge ports in North America, Japan and South Korea will gain access

TSX/NYSE/PSE: MFC SEHK: 945 C$ unless otherwise stated Manulife Financial Corporation (“Manulife” or the “Company”) reported its third quarter results for the period ended September 30, 2025, delivering record core earnings and double-digit growth in core EPS. https://mma.prnewswire.com/media/2821442/Manulife_Financial_Corporation_Manulife_Reports_Third_Quarter_20.jpg Key highlights for the third quarter of 2025 (“3Q25”) include: — Core earnings1 of $2.0 billion, up

C$ unless otherwise stated TSX/NYSE/PSE: MFC SEHK: 945 Manulife's Board of Directors today announced quarterly shareholders' dividends on the following non-cumulative preferred shares of Manulife Financial Corporation, payable on or after December 19, 2025 to shareholders of record at the close of business on November 26, 2025: https://mma.prnewswire.com/media/2819208/Manulife_Financial_Corporation_Manulife%C2%A0declares_preferred_share.jpg — Class A Shares Series 2 –

C$ unless otherwise stated TSX/NYSE/PSE: MFC SEHK: 945 Manulife's Board of Directors today announced a quarterly common shareholders' dividend of $0.44 per share on the common shares of Manulife, payable on and after December 19, 2025, to shareholders of record at the close of business on November 26, 2025. https://mma.prnewswire.com/media/2819189/Manulife_Financial_Corporation_Manulife_declares_common_share_di.jpg In respect of the Company's

(NASDAQ:RGC),(NASDAQ:BYND),(NasdaqGM:ALVO),(NYSE:CWH), NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regencell Bioscience Holdings Limited (NASDAQ:RGC), Beyond Meat, Inc. (NASDAQ:BYND), Alvotech (NASDAQ:ALVO), and Camping World Holdings, Inc. (NYSE:CWH). Our investigations concern whether these companies have violated the federal securities laws

(NASDAQ:SRZN), SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on November 6, 2025, Surrozen granted inducement stock option awards covering an aggregate of

Bragar Eagel & Squire, P.C. Is Investigating Regencell, Beyond Meat, Alvotech, and Camping World and Encourages Investors to Contact the Firm GlobeNewswire November 12, 2025 NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regencell Bioscience Holdings Limited (NASDAQ:RGC),